Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|July 11, 2023

Caribou Biosciences Receives $25 Million Equity Investment from Pfizer

Author(s)Jill Murphy

In addition, Caribou will maintain full ownership and control of its pipeline of allogeneic CAR-T and CAR-NK cell therapies.

Caribou Biosciences announced on July 6, 2023 that Pfizer made a $25 million equity investment in the company, according to a company press release. The purchase by Pfizer closed on June 30, 2023.

“We believe Pfizer’s investment in Caribou highlights the potential of our clinical programs, and we are excited to establish this partnership with one of the world’s premier biopharmaceutical companies,” said Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, in a press release. “We are actively advancing our allogeneic CAR-T cell therapy pipeline and look forward to providing updates from all of our programs over the next six months, including six-month dose escalation data from our ANTLER Phase I clinical trial for CB-010, dose escalation updates on our CaMMouflage Phase I clinical trial for CB-011, and submission of an investigational new drug application for CB-012.”

Caribou will take the investment proceeds to advance CB-011, which is an immune cloaked allogeneic CAR-T cell therapy currently being evaluated in the CaMMouflage Phase I clinical trial in patients with relapsed or refractory multiple myeloma. In addition, Caribou will maintain full ownership and control of its pipeline of allogeneic CAR-T and CAR-NK cell therapies.

Source: Caribou Biosciences


Related to this article

The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.
Close-up of a clear IV infusion bag filled with pale yellow fluid, with a pink awareness ribbon printed on its front, against a gray background. | Image Credit: © Olga - stock.adobe.com
The European Commission has authorized Biocon’s pertuzumab biosimilar Pebrilzo as a HER2-positive breast cancer treatment, the first biosimilar cleared under EMA’s tailored clinical approach, which relies on analytical and pharmacokinetic data in place of a comparative efficacy trial. The EU biosimilar approval follows FDA approval of Pebrilzo two days earlier.